SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2022

SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE

The following table shows the computation of basic net loss per share of common stock for the three and six months ended June 30, 2022 and 2021:

	For the						For the
	Three Months Ended						Six Months Ended
	June 30, 2022			June 30, 2021			June 30, 2022			June 30, 2021
Numerator – net loss attributable to common stockholders	$	(6,239,000	)	$	(2,950,000	)	$	(8,677,000	)	$	(2,733,000	)
Denominator – weighted average
number of shares outstanding, basic and diluted		27,303,458			26,736,970			27,265,350			26,379,943
Net loss per share of common stock, basic and diluted	$	(0.23	)	$	(0.11	)	$	(0.32	)	$	(0.10	)

Melt Pharmaceuticals, Inc. [Member]

SCHEDULE OF INVESTMENT

The following table summarizes the Company’s investments in Melt as of June 30, 2022:

			Share of Equity Method			Paid-in -Kind		In-substance Capital			Net
	Cost Basis		Losses			Interest		Contributions			Carrying value
Common stock	$	5,810,000	$	(5,810,000	)	$	-	$	-		$		-
Loan		13,500,000		(7,899,000	)		1,484,000		(1,484,000	)		5,601,000
	$	19,310,000	$	(13,709,000	)	$	1,484,000	$	(1,484,000	)	$	5,601,000

Surface Ophthalmics, Inc. [Member]

SCHEDULE OF INVESTMENT

The following table summarizes the Company’s investment in Surface as of June 30, 2022:

	Cost		Share of Equity			Net
	Basis		Method Losses			Carrying value
Common stock	$	5,320,000	$	(5,320,000	)	$	-